Newly Minted Downgrade of Some Papillary Cancers as Benign Saves Excessive Surgery and Costs Less.
Agrawal N. et al Endo Practice 23(4) April 2017. The aggressive treatment group’s was twice as expensive for initial treatment for NIFT-P. This was due to unneeded total thyroidectomies, completion surgery, and radioiodine therapy. These are correct for invasive cases, but after the pathology confirms NIFT-P the patient has a benign tumor and should be sent home a happy person, with no cancer on the insurance,
less chance of bankruptcy, and less complications possible from more surgery and radioiodine.
Major complication from low volume surgeons with total thyroidectomies
which are not needed for benign NIFT-P.
- Health care costs in US for thyroid cancer is $1.6 billion.
- 41% of all costs was for surgery, and radioiodine.
- Cancer chronic surveillance was 37% of the costs.
- Thyroid cancer is a leading cause of bankruptcy.
- Renamed non-invasive follicular tumor with look alike papillary cells NIFT-P and not cancer can save the patient the costs,morbidity for cancer treatment that now is not needed.
- Lobectomy is the method of choice to evaluate the capsule for invasion.
- Prior many had completion thyroidectomy or total thyroidectomies, and some with radioiodine therapy.
- With a benign diagnosis for NIFT–P after lobectomy there is no need for any more treatment for cancer.
- THEY NO NOT HAVE CANCER.NO MORE SURGERY.NO RADIOIODINE, AND NO LONG TERM CANCER FOLLOW UP.
- With a benign diagnosis there will be less bankruptcies, less complications from more cancer treatment, and even the possibility with a normal lobe intact there may not have a need for thyroid hormone therapy.
- Say goodbye to your endocrinologist,surgeon, nuclear medicine physician, and the inside of your local hospital again.